Finance Watch: Argenx Raises $1.15bn For Efgartigimod Commercialization
FcRn Antibody Fragment Submitted To US FDA In January
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.
You may also be interested in...
Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
Pipeline-in-a-product approaches have become popular in biopharma, and Gilead has been making significant strides.